Peter C. Richardson

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Valencia, CA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Mark Tyndall, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Peter C. Richardson

Form 4 holding EVP & Chief Scientific Officer

Mallinckrodt plc

Security class
Restricted Stock Units
Shares / value
27,357
Estimated value
Report date
31 Jul 2025
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding EVP & Chief Scientific Officer

Mallinckrodt plc

Security class
Ordinary Shares
Shares / value
3,419
Estimated value
Report date
01 Jan 2025
Price
$37.50
Ownership
Direct
Form 4 holding EVP, Research and Development and Chief Medical Officer

ANTARES PHARMA, INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
24 May 2022
Price
$5.60
Ownership
Direct
Form 4 holding EVP, Research and Development and Chief Medical Officer

ANTARES PHARMA, INC.

Security class
Stock Option (right to buy)
Shares / value
0
Estimated value
Report date
24 May 2022
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Peter C. Richardson

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .